Theravance Biopharma, Inc. (NASDAQ:TBPH) Short Interest Update

Theravance Biopharma, Inc. (NASDAQ:TBPH) was the target of a significant decrease in short interest during the month of August. As of August 14th, there was short interest totaling 1,714,947 shares, a decrease of 58.9% from the July 30th total of 4,168,511 shares. Currently, 3.6% of the shares of the stock are sold short. Based on an average trading volume of 683,553 shares, the days-to-cover ratio is currently 2.5 days.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on TBPH shares. Weiss Ratings raised Theravance Biopharma from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, August 17th. HC Wainwright lowered Theravance Biopharma from a “buy” rating to a “neutral” rating and upped their target price for the stock from $15.00 to $17.00 in a research note on Tuesday, July 7th. JonesTrading cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Monday, June 29th. Zacks Research raised shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 7th. Finally, Wall Street Zen lowered shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. One research analyst has rated the stock with a Strong Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $19.40.

Theravance Biopharma Stock Up 0.1%

NASDAQ TBPH opened at $17.04 on Friday. The company has a 50-day simple moving average of $16.95 and a two-hundred day simple moving average of $16.62. Theravance Biopharma has a 12-month low of $13.08 and a 12-month high of $21.03. The firm has a market cap of $884.72 million, a price-to-earnings ratio of 16.87 and a beta of 0.19.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Monday, August 10th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.07 by ($0.18). Theravance Biopharma had a negative return on equity of 0.77% and a net margin of 51.58%.The company had revenue of $20.73 million during the quarter, compared to analysts’ expectations of $22.49 million. Equities analysts expect that Theravance Biopharma will post 1.56 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Theravance Biopharma news, major shareholder Eli Samaha sold 273,871 shares of Theravance Biopharma stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $17.23, for a total transaction of $4,718,797.33. Following the completion of the sale, the insider owned 9,237,279 shares of the company’s stock, valued at $159,158,317.17. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Rhonda Farnum sold 13,314 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $16.39, for a total value of $218,216.46. Following the completion of the transaction, the senior vice president owned 232,457 shares of the company’s stock, valued at $3,809,970.23. The trade was a 5.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 350,011 shares of company stock worth $6,008,309. 7.65% of the stock is owned by insiders.

Hedge Funds Weigh In On Theravance Biopharma

A number of large investors have recently bought and sold shares of TBPH. Vanguard Group Inc. lifted its position in Theravance Biopharma by 2.5% in the third quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company’s stock valued at $32,289,000 after purchasing an additional 54,152 shares during the last quarter. State Street Corp increased its stake in shares of Theravance Biopharma by 4.4% in the fourth quarter. State Street Corp now owns 1,101,892 shares of the biopharmaceutical company’s stock worth $20,616,000 after buying an additional 45,987 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Theravance Biopharma by 14.5% in the first quarter. Dimensional Fund Advisors LP now owns 983,615 shares of the biopharmaceutical company’s stock worth $15,960,000 after buying an additional 124,658 shares during the period. Geode Capital Management LLC increased its stake in shares of Theravance Biopharma by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 938,724 shares of the biopharmaceutical company’s stock worth $17,567,000 after buying an additional 40,734 shares during the period. Finally, Arrowstreet Capital Limited Partnership bought a new stake in Theravance Biopharma during the 3rd quarter valued at $10,611,000. 99.10% of the stock is owned by hedge funds and other institutional investors.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.